53 completed, 9 recruiting, 2 not yet recruiting, 2 terminated. 70 Phase 1, 15 Phase 2.
Follow Enterobacteriaceae Infections: new trials by email Literature Review of Enterobacteriaceae Infections trials Research Report on Enterobacteriaceae Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Immunogenicity Study of IP-QSV Vaccine in Healthy Adults/Adolescents, Children and Infants 30μg IP-QSV, Placebo, 10μg IP-QSV - Shigella Infection | Phase 1 / Phase 2 | Not yet recruiting | International Vaccine Institute | 370 | 2026-07-01 | 2026-06-24 |
| A Study to Evaluate the Safety, Reactogenicity, and Immune Response of the GSK Vaccines Institute for Global Health (GVGH) Quadrivalent Pan-Salmonella Vaccine With and Without Alum in Healthy Young Adults Pan-Salmonella-with-Alum (Low dose) vaccine, Pan-Salmonella-with-Alum (Full dose) vaccine, Pan-Salmonella-without-Alum (Low dose) vaccine - Salmonella Infections | Phase 1 | Recruiting | GlaxoSmithKline | 196 | 2026-06-24 | 2026-07-28 |
| Safety of Combined Intravenous Antibiotic and Bacteriophage Therapy in Adults With Cystic Fibrosis and Antibiotic-Resistant Lung Infections Intravenous Bacteriophage Cocktail plus Standard IV Antibiotics - CF - Cystic Fibrosis, Klebsiella Pneumoniae Infection | Phase 1 | Not yet recruiting | University of California, San Diego | 30 | 2025-12-31 | 2025-12-12 |
| First in Human Dose Escalation Study Evaluating the Safety and Immunogenicity of IVT's Shigella-04 Vaccine in Healthy Young Adults IVT Shigella-04, Placebo (0.9% saline) - Shigella, Diarrhea | Phase 1 | Recruiting | Inventprise Inc. | 60 | 2025-10-09 | 2025-11-19 |
| Bacteriophage Therapy in Spinal Cord Injury Patients With Bacteriuria Phage Therapy, Placebo - Bacteriuria, Spinal Cord Injuries | Phase 1 | Recruiting | Barbara Trautner | 30 | 2025-02-03 | 2026-05-05 |
| Shigella Sonnei 53G Human Infection Study in Kenyan Adults Shigella sonnei 53G, Ciprofloxacin 500 mg - Shigellosis | Phase 1 | Recruiting | University of Oxford | 70 | 2025-01-21 | 2025-03-13 |
| Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplant Receiving FQ Prophylaxis & Harboring FQR Ecoli Pre-Transplant SNIPR001 consists of genetically modified bacteriophages specifically targeting Escherichia coli, Placebo 10 mL - E Coli Infections, Allogenic Transplant Patients | Phase 1 / Phase 2 | Recruiting | SNIPR Biome Aps. | 66 | 2024-12-04 | 2026-10-08 |
| A Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy in Females 18-64 Years of Age Candidate UTI vaccine low dose formulation 1, Candidate UTI vaccine low dose formulation 2, Candidate UTI vaccine medium dose formulation 1 - Urinary Tract Infections | Phase 1 / Phase 2 | Recruiting | GlaxoSmithKline | 448 | 2024-11-19 | 2026-04-21 |
| InvaplexAR-Detox and DmLT Adjuvant in the Netherlands and Zambia 2.5 μg InvaplexAR-Detox, 10 μg InvaplexAR-Detox, 0.1 μg of dmLT - Shigellosis, Bacillary Dysentery | Phase 1 | Recruiting | Leiden University Medical Center | 85 | 2024-10-10 | 2024-11-07 |
| FMT to Eradicate Intestinal Colonization by Carbapenem-resistant Enterobacteriaceae Donor - FMT, Placebo FMT - Enterobacteriaceae Infections, Multi-antibiotic Resistance | Phase 1 / Phase 2 | Recruiting | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 36 | 2024-02-08 | 2025-03-12 |
| ShigETEC Vaccine Study in Bangladesh ShigETEC live, attenuated, oral vaccine, Placebo - Healthy Volunteers | Phase 1 | Completed | Eveliqure Biotechnologies GmbH | 196 | 2023-11-26 | 2026-01-23 |
| Safety, Tolerability, and Immunogenicity of Recombinant Meningococcal Group B Vaccine (E.Coli) Recombinant Meningococcal Group B Vaccine (E. Coli) (low-dose), Recombinant Meningococcal Group B Vaccine (E. Coli) (hign-dose), Placebo control - Healthy Volunteers | Phase 1 | Unknown | Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd | 300 | 2023-07-22 | 2024-04-03 |
| Safety and Efficacy of the Bacteriophage Preparation, ShigActive™, in a Human Experimental Model of Shigellosis bacteriophage, Placebo - Shigellosis | Phase 1 / Phase 2 | Active not recruiting | Intralytix, Inc. | 52 | 2023-02-23 | 2025-06-15 |
| Safety and Immunogenicity of a Novel Conjugate Vaccine Against Salmonella Typhi and Salmonella Paratyphi A in Healthy Adults TYP04A Low Dose without Alum investigational vaccine, TYP04B Full Dose without Alum investigational vaccine, TYP03A Low Dose with Alum investigational vaccine - Typhoid Fever | Phase 1 | Completed | GlaxoSmithKline | 97 | 2022-11-28 | 2025-01-24 |
| Shigella CVD 31000: Study of Responses With Shigella-ETEC Vaccine Strain CVD 1208S-122 strain CVD 1208S-122, Placebo - Shigella Infection, Enterotoxigenic Escherichia Coli Infection | Phase 1 | Completed | University of Maryland, Baltimore | 53 | 2022-09-29 | 2026-02-02 |
| A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella and Typhoid Fever Invasive nontyphoidal Salmonella-typhoid conjugate vaccine (iNTS-TCV) low dose, Invasive nontyphoidal Salmonella-generalized modules for membrane antigens vaccine (iNTS-GMMA) low dose, Typhoid conjugate vaccine (TCV) low dose - Salmonella Infections | Phase 1 / Phase 2 | Completed | GlaxoSmithKline | 155 | 2022-09-13 | 2025-11-28 |
| Efficacy Of Doxycycline & Versus Rifampin In Treatment Of Rhinoscleroma Doxycycline, Ciprofloxacin, Rifampin - Rhinoscleroma | Phase 1 | Unknown | Assiut University | 45 | 2022-08-21 | 2022-07-07 |
| Non-inferiority Trial of Locally Manufactured Typhoid Conjugate Vaccine 'Typhocon' in Bangladesh Typhoid Vi polysaccharide-diphtheria toxoid conjugate vaccine (Vi-DT) - Typhoid | Phase 1 / Phase 2 | Completed | International Centre for Diarrhoeal Disease Research, Bangladesh | 630 | 2022-07-01 | 2024-12-24 |
| Safety, Tolerability, Pharmacokinetic and Microbiological Investigation of GSK3882347 in Female Participants With Urinary Tract Infections GSK3882347, Nitrofurantoin, Placebo - Uncomplicated Urinary Tract Infections, Urinary Tract Infections | Phase 1 | Completed | GlaxoSmithKline | 140 | 2022-05-18 | 2026-03-13 |
| Controlled Human Infection Model Challenge/Rechallenge Shigella sonnei 53G, Shigella flexneri 2a 2457T - Shigellosis | Phase 1 | Completed | PATH | 46 | 2022-04-26 | 2025-01-31 |
Showing 20 of 70. Sign in to see all of them.
Dysentery, Bacillary (31) · Escherichia coli Infections (19) · Typhoid Fever (12) · Diarrhea (10) · Urinary Tract Infections (5) · Dysentery (4) · Plague (3) · Spinal Cord Injuries (3) · Cholera (2) · Gastrointestinal Diseases (2) · Paratyphoid Fever (2) · Salmonella Infections (2) · Arthritis, Reactive (1) · Bacterial Infections (1)
Bacterial Infections and Mycoses (70) · Infections (70) · Bacterial Infections (69) · Gram-Negative Bacterial Infections (69) · Digestive System Diseases (33) · Gastroenteritis (31) · Intestinal Diseases (31) · Gastrointestinal Diseases (30) · Dysentery (27) · Pathological Conditions, Signs and Symptoms (12) · Salmonella Infections (12) · Signs and Symptoms (11) · Signs and Symptoms, Digestive (10) · Female Urogenital Diseases (6)
Vaccines (8) · Vi polysaccharide vaccine, typhoid (6) · Boostrix (3) · Ciprofloxacin (3) · Adjuvants, Pharmaceutic (2) · Meningococcal Vaccines (2) · Sodium Chloride (2) · Adjuvants, Vaccine (1) · Albendazole (1) · Aluminum Hydroxide (1) · Arsenic (1) · Cefpodoxime Proxetil (1) · Doxycycline (1) · Fluzone High-Dose (1) · Hepatitis A Vaccines (1)
National Institute of Allergy and Infectious Diseases (NIAID) (9) · GlaxoSmithKline (7) · PATH (7) · U.S. Army Medical Research and Development Command (6) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (4) · Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd (2) · Eveliqure Biotechnologies GmbH (2) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (2) · GSK Vaccines Institute For Global Health S.r.l. (2) · International Centre for Diarrhoeal Disease Research, Bangladesh (2) · International Vaccine Institute (2) · LimmaTech Biologics AG (2) · US Department of Veterans Affairs (2) · University of Maryland, Baltimore (2) · Assiut University (1)
United States (36) · Bangladesh (6) · Belgium (4) · Kenya (3) · United Kingdom (3) · China (2) · France (2) · Israel (2) · Italy (2) · South Africa (2) · Australia (1) · Hungary (1) · Malawi (1) · Netherlands (1) · Philippines (1)
Barbara Trautner, MD (2) · Ahmed AbdelAleem, PhD (1) · Alexander Sulakvelidze, PhD (1) · Barbara W Trautner, MD (1) · Barbara W Trautner, MD, PhD (1) · Carl Mason, MD (1) · Christoph Hatz, Prof. Dr. (1) · Christopher Duplessis, MD, MPH, MS (1) · Clayton D Harro, MD, ScM (1) · Cornelia Dekker, MD (1) · David JM Lewis, MD (1) · David Tribble, MD, PhD (1)
PMID 27490698, PMID 28735965, PMID 34017343, PMID 10334980, PMID 10471979, PMID 1928194, PMID 20619378, PMID 21813209, PMID 21980445, PMID 24657719, PMID 25410205, PMID 26048203, PMID 26162850, PMID 2644914, PMID 26865592, PMID 27146000, PMID 27581434, PMID 29534721, PMID 29776750, PMID 3046725, PMID 30473185, PMID 31757774, PMID 31905228, PMID 33186516, PMID 33207794, PMID 33807097, PMID 33849723, PMID 34793505, PMID 35536001, PMID 37666695, PMID 38853614, PMID 39852827, PMID 39893179, PMID 40152601, PMID 41306922, PMID 41587557, PMID 41999631, PMID 42234814, PMID 597710, PMID 6363727
2016 (1), R01AI130398 (1)